Literature DB >> 16015177

MRI evaluation of neurofibromatosis 2 patients: a standardized approach for accuracy in interpretation.

William H Slattery1, Michael H Lev, Laurel M Fisher, Sarah S Connell, Zarina Iqbal, John L Go.   

Abstract

OBJECTIVE: To determine the level of agreement between local radiologists' and an experienced neuroradiologist's measurements of vestibular schwannomas. STUDY
DESIGN: Prospective study with uniform magnetic resonance acquisition protocol parameters and reporting instructions across 30 magnetic resonance imaging facilities worldwide.
SETTING: Multicenter natural history study of neurofibromatosis Type 2.
SUBJECTS: One hundred fifteen magnetic resonance imaging examinations of 57 neurofibromatosis Type 2 patients older than 5 years of age.
INTERVENTIONS: Thin-slice, postcontrast cranial magnetic resonance imaging. MAIN OUTCOME MEASURES: Spearman's rho interobserver association coefficient of vestibular schwannoma linear measurements.
RESULTS: The local and experienced radiologist measurements and identification of tumors agreement was fair (kappa = 0.77). Discordant interpretations were adjudicated by another experienced neuroradiologist.
CONCLUSION: The least interobserver variability was found in measurements of thin-slice postcontrast magnetic resonance imaging scans obtained at neurofibromatosis Type 2 centers in patients without previous operations and moderately sized tumors. If the schwannoma was difficult to assess, because of magnetic resonance imaging acquisition protocol, postoperative changes, or tumors smaller than 5 mm in greatest diameter, the neuroradiologist provided a more thorough assessment. The authors suggest uniform reporting criteria for vestibular schwannoma assessments to ensure clinically relevant information is communicated regarding vestibular schwannoma size.

Entities:  

Mesh:

Year:  2005        PMID: 16015177     DOI: 10.1097/01.mao.0000169048.15889.80

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  6 in total

1.  Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors.

Authors:  Michael S Dirks; John A Butman; H Jeffrey Kim; Tianxia Wu; Keaton Morgan; Anne P Tran; Russell R Lonser; Ashok R Asthagiri
Journal:  J Neurosurg       Date:  2012-04-13       Impact factor: 5.115

Review 2.  Meningiomas and neurofibromatosis.

Authors:  Stéphane Goutagny; Michel Kalamarides
Journal:  J Neurooncol       Date:  2010-08-17       Impact factor: 4.130

3.  Comparing size evaluation methods for acoustic neuroma after stereotactic radiosurgery.

Authors:  Anneyuko I Saito; Christopher G Morris; Kana Ito; Futoshi Watanabe; Kumiko Karasawa; William M Mendenhall; Yutaka Naoi
Journal:  Radiat Med       Date:  2007-08-27

Review 4.  Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

Authors:  Scott R Plotkin; Chris Halpin; Jaishri O Blakeley; William H Slattery; D Bradley Welling; Susan M Chang; Jay S Loeffler; Gordon J Harris; A Gregory Sorensen; Michael J McKenna; Fred G Barker
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

5.  Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.

Authors:  D Gareth Evans; Marco Giovannini; Michel Kalamarides; Kim Hunter-Schaedle; Jaishri Blakeley; Jeffrey Allen; Dusica Babovic-Vuskanovic; Allan Belzberg; Gideon Bollag; Ruihong Chen; Emmanuelle DiTomaso; John Golfinos; Gordon Harris; Abraham Jacob; Ganjam Kalpana; Matthias Karajannis; Bruce Korf; Razelle Kurzrock; Meng Law; Andrea McClatchey; Roger Packer; Pamela Roehm; Allan Rubenstein; William Slattery; James H Tonsgard; D Bradley Welling; Brigitte Widemann; Kaleb Yohay
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

6.  Mechanisms of hearing loss in neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Raul A Vasquez; John A Butman; Tianxia Wu; Keaton Morgan; Carmen C Brewer; Kelly King; Chris Zalewski; H Jeffrey Kim; Russell R Lonser
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.